Study on HER2 Directed Dendritic Cell Vaccine with Weekly Paclitaxel, Trastuzumab, and Pertuzumab

Inclusion Criteria

• Have a confirmed diagnosis of stage I-III HER2-positive breast cancer, with a primary tumor measuring at least 1 cm.
• Be eligible for chemotherapy with Paclitaxel, Trastuzumab, and Pertuzumab before surgery, as decided by your doctor.
• Be in good overall health, with an ECOG performance status of 0 or 1, meaning fully active or restricted in physically strenuous activity but ambulatory.
• Have normal organ and bone marrow function based on specific medical tests.
• Have a normal heart function as shown by a heart scan or echocardiogram.
• Women who can become pregnant and their male partners must agree to use effective birth control during the study. If a woman becomes pregnant or thinks she might be, she should inform her doctor immediately. Men should use a barrier method or abstain from sex during chemotherapy until surgery.
• Be able to understand and willing to sign a consent form to participate in the study.

Exclusion Criteria

• Have inflammatory breast cancer or advanced breast cancer that cannot be surgically removed, or if the cancer has spread to other parts of the body.
• Be receiving any other experimental treatments for breast cancer.
• Have a history of allergic reactions to similar vaccines or any of the chemotherapy drugs used in the study.
• Be unable or unwilling to undergo a procedure to collect cells for the vaccine.
• Have uncontrolled health issues, such as ongoing infections, heart failure, unstable chest pain, irregular heartbeats, or mental health conditions that would make it hard to follow the study requirements.
• Be pregnant or breastfeeding.
• Have a known immune deficiency or require immune-suppressing drugs for conditions like autoimmune diseases or organ transplants.